11 results on '"Karray H"'
Search Results
2. PP026 [Infections » Covid-19 / Sars-CoV-2]: SEVERE COVID19 INFECTION WHILE PREGNANCY: MATERNAL AND NEONATAL IMPACT
- Author
-
Haj Ltaief, M., primary, Regaieg, C., additional, Baccouche, N., additional, Gargouri, S., additional, Kolsi, N., additional, Charfi, M., additional, Ben Hamed, A., additional, Hmida, N., additional, Regaieg, R., additional, Ben Thabet, A., additional, Karray, H., additional, Bouaziz, M., additional, Bouraoui, A., additional, and Gargouri, A., additional
- Published
- 2022
- Full Text
- View/download PDF
3. The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance
- Author
-
Tegally, H, San, JE, Cotten, M, Moir, M, Tegomoh, B, Mboowa, G, Martin, DP, Baxter, C, Lambisia, AW, Diallo, A, Amoako, DG, Diagne, MM, Sisay, A, Zekri, A-RN, Gueye, AS, Sangare, AK, Ouedraogo, A-S, Sow, A, Musa, AO, Sesay, AK, Abias, AG, Elzagheid, A, Lagare, A, Kemi, A-S, Abar, AE, Johnson, AA, Fowotade, A, Oluwapelumi, AO, Amuri, AA, Juru, A, Kandeil, A, Mostafa, A, Rebai, A, Sayed, A, Kazeem, A, Balde, A, Christoffels, A, Trotter, AJ, Campbell, A, Keita, AK, Kone, A, Bouzid, A, Souissi, A, Agweyu, A, Naguib, A, Gutierrez, A, Nkeshimana, A, Page, AJ, Yadouleton, A, Vinze, A, Happi, AN, Chouikha, A, Iranzadeh, A, Maharaj, A, Batchi-Bouyou, AL, Ismail, A, Sylverken, AA, Goba, A, Femi, A, Sijuwola, AE, Marycelin, B, Salako, BL, Oderinde, BS, Bolajoko, B, Diarra, B, Herring, BL, Tsofa, B, Lekana-Douki, B, Mvula, B, Njanpop-Lafourcade, B-M, Marondera, BT, Khaireh, BA, Kouriba, B, Adu, B, Pool, B, McInnis, B, Brook, C, Williamson, C, Nduwimana, C, Anscombe, C, Pratt, CB, Scheepers, C, Akoua-Koffi, CG, Agoti, CN, Mapanguy, CM, Loucoubar, C, Onwuamah, CK, Ihekweazu, C, Malaka, CN, Peyrefitte, C, Grace, C, Omoruyi, CE, Rafai, CD, Morang'a, CM, Erameh, C, Lule, DB, Bridges, DJ, Mukadi-Bamuleka, D, Park, D, Rasmussen, DA, Baker, D, Nokes, DJ, Ssemwanga, D, Tshiabuila, D, Amuzu, DSY, Goedhals, D, Grant, DS, Omuoyo, DO, Maruapula, D, Wanjohi, DW, Foster-Nyarko, E, Lusamaki, EK, Simulundu, E, Ong'era, EM, Ngabana, EN, Abworo, EO, Otieno, E, Shumba, E, Barasa, E, Ahmed, EB, Ahmed, EA, Lokilo, E, Mukantwari, E, Philomena, E, Belarbi, E, Simon-Loriere, E, Anoh, EA, Manuel, E, Leendertz, F, Taweh, FM, Wasfi, F, Abdelmoula, F, Takawira, FT, Derrar, F, Ajogbasile, F, Treurnicht, F, Onikepe, F, Ntoumi, F, Muyembe, FM, Ragomzingba, FEZ, Dratibi, FA, Iyanu, F-A, Mbunsu, GK, Thilliez, G, Kay, GL, Akpede, GO, van Zyl, GU, Awandare, GA, Kpeli, GS, Schubert, G, Maphalala, GP, Ranaivoson, HC, Omunakwe, HE, Onywera, H, Abe, H, Karray, H, Nansumba, H, Triki, H, Kadjo, HAA, Elgahzaly, H, Gumbo, H, Mathieu, H, Kavunga-Membo, H, Smeti, I, Olawoye, IB, Adetifa, IMO, Odia, I, Ben Boubaker, IB, Mohammad, IA, Ssewanyana, I, Wurie, I, Konstantinus, IS, Halatoko, JWA, Ayei, J, Sonoo, J, Makangara, J-CC, Tamfum, J-JM, Heraud, J-M, Shaffer, JG, Giandhari, J, Musyoki, J, Nkurunziza, J, Uwanibe, JN, Bhiman, JN, Yasuda, J, Morais, J, Kiconco, J, Sandi, JD, Huddleston, J, Odoom, JK, Morobe, JM, Gyapong, JO, Kayiwa, JT, Okolie, JC, Xavier, JS, Gyamfi, J, Wamala, JF, Bonney, JHK, Nyandwi, J, Everatt, J, Nakaseegu, J, Ngoi, JM, Namulondo, J, Oguzie, JU, Andeko, JC, Lutwama, JJ, Mogga, JJH, O'Grady, J, Siddle, KJ, Victoir, K, Adeyemi, KT, Tumedi, KA, Carvalho, KS, Mohammed, KS, Dellagi, K, Musonda, KG, Duedu, KO, Fki-Berrajah, L, Singh, L, Kepler, LM, Biscornet, L, Martins, LDO, Chabuka, L, Olubayo, L, Ojok, LD, Deng, LL, Ochola-Oyier, L, Tyers, L, Mine, M, Ramuth, M, Mastouri, M, ElHefnawi, M, Mbanne, M, Matsheka, M, Kebabonye, M, Diop, M, Momoh, M, Lima Mendonca, MDL, Venter, M, Paye, MF, Faye, M, Nyaga, MM, Mareka, M, Damaris, M-M, Mburu, MW, Mpina, MG, Owusu, M, Wiley, MR, Tatfeng, MY, Ayekaba, MO, Abouelhoda, M, Beloufa, MA, Seadawy, MG, Khalifa, MK, Matobo, MM, Kane, M, Salou, M, Mbulawa, MB, Mwenda, M, Allam, M, Phan, MVT, Abid, N, Rujeni, N, Abuzaid, N, Ismael, N, Elguindy, N, Top, NM, Dia, N, Mabunda, N, Hsiao, N-Y, Silochi, NB, Francisco, NM, Saasa, N, Bbosa, N, Murunga, N, Gumede, N, Wolter, N, Sitharam, N, Ndodo, N, Ajayi, NA, Tordo, N, Mbhele, N, Razanajatovo, NH, Iguosadolo, N, Mba, N, Kingsley, OC, Sylvanus, O, Femi, O, Adewumi, OM, Testimony, O, Ogunsanya, OA, Fakayode, O, Ogah, OE, Oludayo, O-E, Faye, O, Smith-Lawrence, P, Ondoa, P, Combe, P, Nabisubi, P, Semanda, P, Oluniyi, PE, Arnaldo, P, Quashie, PK, Okokhere, PO, Bejon, P, Dussart, P, Bester, PA, Mbala, PK, Kaleebu, P, Abechi, P, El-Shesheny, R, Joseph, R, Aziz, RK, Essomba, RG, Ayivor-Djanie, R, Njouom, R, Phillips, RO, Gorman, R, Kingsley, RA, Neto Rodrigues, RMDESA, Audu, RA, Carr, RAA, Gargouri, S, Masmoudi, S, Bootsma, S, Sankhe, S, Mohamed, SI, Femi, S, Mhalla, S, Hosch, S, Kassim, SK, Metha, S, Trabelsi, S, Agwa, SH, Mwangi, SW, Doumbia, S, Makiala-Mandanda, S, Aryeetey, S, Ahmed, SS, Ahmed, SM, Elhamoumi, S, Moyo, S, Lutucuta, S, Gaseitsiwe, S, Jalloh, S, Andriamandimby, SF, Oguntope, S, Grayo, S, Lekana-Douki, S, Prosolek, S, Ouangraoua, S, van Wyk, S, Schaffner, SF, Kanyerezi, S, Ahuka-Mundeke, S, Rudder, S, Pillay, S, Nabadda, S, Behillil, S, Budiaki, SL, van der Werf, S, Mashe, T, Mohale, T, Le-Viet, T, Velavan, TP, Schindler, T, Maponga, TG, Bedford, T, Anyaneji, UJ, Chinedu, U, Ramphal, U, George, UE, Enouf, V, Nene, V, Gorova, V, Roshdy, WH, Karim, WA, Ampofo, WK, Preiser, W, Choga, WT, Ahmed, YA, Ramphal, Y, Bediako, Y, Naidoo, Y, Butera, Y, de Laurent, ZR, Ouma, AEO, von Gottberg, A, Githinji, G, Moeti, M, Tomori, O, Sabeti, PC, Sall, AA, Oyola, SO, Tebeje, YK, Tessema, SK, de Oliveira, T, Happi, C, Lessells, R, Nkengasong, J, Wilkinson, E, Tegally, H, San, JE, Cotten, M, Moir, M, Tegomoh, B, Mboowa, G, Martin, DP, Baxter, C, Lambisia, AW, Diallo, A, Amoako, DG, Diagne, MM, Sisay, A, Zekri, A-RN, Gueye, AS, Sangare, AK, Ouedraogo, A-S, Sow, A, Musa, AO, Sesay, AK, Abias, AG, Elzagheid, A, Lagare, A, Kemi, A-S, Abar, AE, Johnson, AA, Fowotade, A, Oluwapelumi, AO, Amuri, AA, Juru, A, Kandeil, A, Mostafa, A, Rebai, A, Sayed, A, Kazeem, A, Balde, A, Christoffels, A, Trotter, AJ, Campbell, A, Keita, AK, Kone, A, Bouzid, A, Souissi, A, Agweyu, A, Naguib, A, Gutierrez, A, Nkeshimana, A, Page, AJ, Yadouleton, A, Vinze, A, Happi, AN, Chouikha, A, Iranzadeh, A, Maharaj, A, Batchi-Bouyou, AL, Ismail, A, Sylverken, AA, Goba, A, Femi, A, Sijuwola, AE, Marycelin, B, Salako, BL, Oderinde, BS, Bolajoko, B, Diarra, B, Herring, BL, Tsofa, B, Lekana-Douki, B, Mvula, B, Njanpop-Lafourcade, B-M, Marondera, BT, Khaireh, BA, Kouriba, B, Adu, B, Pool, B, McInnis, B, Brook, C, Williamson, C, Nduwimana, C, Anscombe, C, Pratt, CB, Scheepers, C, Akoua-Koffi, CG, Agoti, CN, Mapanguy, CM, Loucoubar, C, Onwuamah, CK, Ihekweazu, C, Malaka, CN, Peyrefitte, C, Grace, C, Omoruyi, CE, Rafai, CD, Morang'a, CM, Erameh, C, Lule, DB, Bridges, DJ, Mukadi-Bamuleka, D, Park, D, Rasmussen, DA, Baker, D, Nokes, DJ, Ssemwanga, D, Tshiabuila, D, Amuzu, DSY, Goedhals, D, Grant, DS, Omuoyo, DO, Maruapula, D, Wanjohi, DW, Foster-Nyarko, E, Lusamaki, EK, Simulundu, E, Ong'era, EM, Ngabana, EN, Abworo, EO, Otieno, E, Shumba, E, Barasa, E, Ahmed, EB, Ahmed, EA, Lokilo, E, Mukantwari, E, Philomena, E, Belarbi, E, Simon-Loriere, E, Anoh, EA, Manuel, E, Leendertz, F, Taweh, FM, Wasfi, F, Abdelmoula, F, Takawira, FT, Derrar, F, Ajogbasile, F, Treurnicht, F, Onikepe, F, Ntoumi, F, Muyembe, FM, Ragomzingba, FEZ, Dratibi, FA, Iyanu, F-A, Mbunsu, GK, Thilliez, G, Kay, GL, Akpede, GO, van Zyl, GU, Awandare, GA, Kpeli, GS, Schubert, G, Maphalala, GP, Ranaivoson, HC, Omunakwe, HE, Onywera, H, Abe, H, Karray, H, Nansumba, H, Triki, H, Kadjo, HAA, Elgahzaly, H, Gumbo, H, Mathieu, H, Kavunga-Membo, H, Smeti, I, Olawoye, IB, Adetifa, IMO, Odia, I, Ben Boubaker, IB, Mohammad, IA, Ssewanyana, I, Wurie, I, Konstantinus, IS, Halatoko, JWA, Ayei, J, Sonoo, J, Makangara, J-CC, Tamfum, J-JM, Heraud, J-M, Shaffer, JG, Giandhari, J, Musyoki, J, Nkurunziza, J, Uwanibe, JN, Bhiman, JN, Yasuda, J, Morais, J, Kiconco, J, Sandi, JD, Huddleston, J, Odoom, JK, Morobe, JM, Gyapong, JO, Kayiwa, JT, Okolie, JC, Xavier, JS, Gyamfi, J, Wamala, JF, Bonney, JHK, Nyandwi, J, Everatt, J, Nakaseegu, J, Ngoi, JM, Namulondo, J, Oguzie, JU, Andeko, JC, Lutwama, JJ, Mogga, JJH, O'Grady, J, Siddle, KJ, Victoir, K, Adeyemi, KT, Tumedi, KA, Carvalho, KS, Mohammed, KS, Dellagi, K, Musonda, KG, Duedu, KO, Fki-Berrajah, L, Singh, L, Kepler, LM, Biscornet, L, Martins, LDO, Chabuka, L, Olubayo, L, Ojok, LD, Deng, LL, Ochola-Oyier, L, Tyers, L, Mine, M, Ramuth, M, Mastouri, M, ElHefnawi, M, Mbanne, M, Matsheka, M, Kebabonye, M, Diop, M, Momoh, M, Lima Mendonca, MDL, Venter, M, Paye, MF, Faye, M, Nyaga, MM, Mareka, M, Damaris, M-M, Mburu, MW, Mpina, MG, Owusu, M, Wiley, MR, Tatfeng, MY, Ayekaba, MO, Abouelhoda, M, Beloufa, MA, Seadawy, MG, Khalifa, MK, Matobo, MM, Kane, M, Salou, M, Mbulawa, MB, Mwenda, M, Allam, M, Phan, MVT, Abid, N, Rujeni, N, Abuzaid, N, Ismael, N, Elguindy, N, Top, NM, Dia, N, Mabunda, N, Hsiao, N-Y, Silochi, NB, Francisco, NM, Saasa, N, Bbosa, N, Murunga, N, Gumede, N, Wolter, N, Sitharam, N, Ndodo, N, Ajayi, NA, Tordo, N, Mbhele, N, Razanajatovo, NH, Iguosadolo, N, Mba, N, Kingsley, OC, Sylvanus, O, Femi, O, Adewumi, OM, Testimony, O, Ogunsanya, OA, Fakayode, O, Ogah, OE, Oludayo, O-E, Faye, O, Smith-Lawrence, P, Ondoa, P, Combe, P, Nabisubi, P, Semanda, P, Oluniyi, PE, Arnaldo, P, Quashie, PK, Okokhere, PO, Bejon, P, Dussart, P, Bester, PA, Mbala, PK, Kaleebu, P, Abechi, P, El-Shesheny, R, Joseph, R, Aziz, RK, Essomba, RG, Ayivor-Djanie, R, Njouom, R, Phillips, RO, Gorman, R, Kingsley, RA, Neto Rodrigues, RMDESA, Audu, RA, Carr, RAA, Gargouri, S, Masmoudi, S, Bootsma, S, Sankhe, S, Mohamed, SI, Femi, S, Mhalla, S, Hosch, S, Kassim, SK, Metha, S, Trabelsi, S, Agwa, SH, Mwangi, SW, Doumbia, S, Makiala-Mandanda, S, Aryeetey, S, Ahmed, SS, Ahmed, SM, Elhamoumi, S, Moyo, S, Lutucuta, S, Gaseitsiwe, S, Jalloh, S, Andriamandimby, SF, Oguntope, S, Grayo, S, Lekana-Douki, S, Prosolek, S, Ouangraoua, S, van Wyk, S, Schaffner, SF, Kanyerezi, S, Ahuka-Mundeke, S, Rudder, S, Pillay, S, Nabadda, S, Behillil, S, Budiaki, SL, van der Werf, S, Mashe, T, Mohale, T, Le-Viet, T, Velavan, TP, Schindler, T, Maponga, TG, Bedford, T, Anyaneji, UJ, Chinedu, U, Ramphal, U, George, UE, Enouf, V, Nene, V, Gorova, V, Roshdy, WH, Karim, WA, Ampofo, WK, Preiser, W, Choga, WT, Ahmed, YA, Ramphal, Y, Bediako, Y, Naidoo, Y, Butera, Y, de Laurent, ZR, Ouma, AEO, von Gottberg, A, Githinji, G, Moeti, M, Tomori, O, Sabeti, PC, Sall, AA, Oyola, SO, Tebeje, YK, Tessema, SK, de Oliveira, T, Happi, C, Lessells, R, Nkengasong, J, and Wilkinson, E
- Abstract
Investment in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing in Africa over the past year has led to a major increase in the number of sequences that have been generated and used to track the pandemic on the continent, a number that now exceeds 100,000 genomes. Our results show an increase in the number of African countries that are able to sequence domestically and highlight that local sequencing enables faster turnaround times and more-regular routine surveillance. Despite limitations of low testing proportions, findings from this genomic surveillance study underscore the heterogeneous nature of the pandemic and illuminate the distinct dispersal dynamics of variants of concern-particularly Alpha, Beta, Delta, and Omicron-on the continent. Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve while the continent faces many emerging and reemerging infectious disease threats. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century.
- Published
- 2022
4. Quand le COVID-19 chatouille les gros vaisseaux … !
- Author
-
Guermazi, M., primary, Awa, J., additional, Derbel, A., additional, Frikha, O., additional, Zouari, F., additional, Hwidi, M., additional, Douib, Z., additional, Berrajah, L., additional, Karray, H., additional, Mnif, Z., additional, Marzouk, S., additional, and Bahloul, Z., additional
- Published
- 2021
- Full Text
- View/download PDF
5. SEVERE COVID19 INFECTION WHILE PREGNANCY: MATERNAL AND NEONATAL IMPACT.
- Author
-
Ltaief, M. Haj, Regaieg, C., Baccouche, N., Gargouri, S., Kolsi, N., Charfi, M., Ben Hamed, A., Hmida, N., Regaieg, R., Ben Thabet, A., Karray, H., Bouaziz, M., Bouraoui, A., and Gargouri, A.
- Published
- 2022
6. Reliability of the rapid antigen test for diagnosis of SARS-CoV-2 in Tunisia.
- Author
-
Chtourou A, Gargouri S, Nasri A, Taktak A, Smaoui F, Chakroun O, Rekik N, Hammami A, Feki-Berrajah L, and Karray H
- Subjects
- Reproducibility of Results, SARS-CoV-2, Nasopharynx virology, Tunisia, COVID-19 Nucleic Acid Testing standards, Sensitivity and Specificity, Predictive Value of Tests, Humans, COVID-19 diagnosis, COVID-19 Serological Testing standards
- Abstract
Background: Early and accurate diagnosis is crucial for preventing the spread of SARS-CoV-2 infection. The rapid antigen test was developed for testing infection, and it was necessary to assess its performance before widespread use in Tunisia., Aim: To evaluate the effectiveness of a rapid antigen test for the detection of SARS-CoV-2 in nasopharyngeal swabs in Tunisia., Methods: Nasopharyngeal samples were taken from COVID-19 suspected cases between October and December 2020 and tested using the Standard Q COVID-19 Ag test (SD-Biosensor, Republic of Korea) and real-time reverse transcription polymerase chain reaction (RT‑PCR)., Results: Overall, 4539 patients were tested. Of the total study population (N = 4539), 82.5% of positive samples remained positive with the rapid antigen test, while 20.2% (470/2321) of samples that were negative with rapid antigen test were confirmed positive with RT-PCR, giving a negative predictive value of 79.8% for the rapid antigen test. The sensitivity and negative predictive value of the rapid antigen test were 70.2% and 65.8%, respectively. These results improved to 96.4% and 92.8%, respectively, when considering the cycle threshold value by RT-PCR below 25., Conclusion: Although the rapid antigen test was less sensitive than RT-PCR, its ability to rapidly detect individuals with high viral loads makes it suitable for use during an epidemic., (Copyright: © Authors 2024; Licensee: World Health Organization. EMHJ is an open access journal. All papers published in EMHJ are available under the Creative Commons Attribution Non-Commercial ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).)
- Published
- 2024
- Full Text
- View/download PDF
7. Large spontaneous HBV DNA fluctuations and potential usefulness of a single-point measurement of combined HBV DNA and quantitative HBsAg for the exclusion of HBeAg-negative chronic hepatitis B: A prospective Tunisian cohort study.
- Author
-
Chtourou A, Gargouri S, Elleuch E, Feki L, Smaoui F, Taktak A, Mnif K, Kassis M, Hammami A, Ben Jemaa M, and Karray H
- Subjects
- Humans, Hepatitis B e Antigens, DNA, Viral, Cohort Studies, Prospective Studies, Hepatitis B virus genetics, Hepatitis B Surface Antigens, Hepatitis B, Chronic complications
- Abstract
Background and Study Aim: During the natural course of HBeAg-negative chronic hepatitis B (CHB), fluctuations in hepatitis B virus (HBV) DNA and alanine aminotransferase (ALT) levels are often observed, making the classification of patients difficult. We aimed to describe spontaneous short-term HBV DNA level fluctuations and to assess the usefulness of qHBsAg in Tunisian patients with HBeAg-negative chronic HBV infection., Patients and Methods: We included 174 treatment-naive Tunisian patients with HBeAg-negative chronic HBeAg-negative HBV infection. A prospective 1-year follow-up was conducted with serial determinations of HBV DNA, ALT levels, and qHBsAg. The patients were classified into three groups: inactive carriers (G1), patients with negative HBeAg CHB (G2), and patients with an "indeterminate state" (G3). For the latter group, a liver biopsy was indicated., Results: Only genotype D was detected. During follow-up, 21.6% and 19.5% of patients with a low initial (<2,000 IU/ml) and intermediate viral load (2,000-20,000 IU/ml) experienced a subsequent increase in their HBV DNA levels above 2,000 and 20,000 IU/ml, respectively. Significant variations in viral load were observed in 61.1% of patients at 6-month intervals. Among the 174 patients, 89 (51.1%) belonged to G1, 33 (19%) to G2, and 52 (29.9%) to G3. Fourteen patients have undergone a liver biopsy, of whom seven showed moderate to severe liver disease. Combination of HBV DNA < 2,000 IU/ml and qHBsAg < 832 IU/ml excluded CHB in 98.4% of cases. A cutoff point for qHBsAg < 100 IU/ml associated with an annual decline of > 0.5 log
10 IU/ml is a good predictor marker of functional cure for hepatitis B., Conclusions: This study highlights the large short-term fluctuations in HBV DNA in patients with HBeAg-negative chronic HBeAg-negative HBV infection with genotype D. Thus, using the cutoff value of 832 for qHBsAg combined with that of 2,000 for HBV DNA makes it possible to exclude CHB for most patients., Competing Interests: Declaration of competing interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
8. The Delta variant wave in Tunisia: Genetic diversity, spatio-temporal distribution and evidence of the spread of a divergent AY.122 sub-lineage.
- Author
-
Haddad-Boubaker S, Arbi M, Souiai O, Chouikha A, Fares W, Edington K, Sims S, Camma C, Lorusso A, Diagne MM, Diallo A, Boubaker IBB, Ferjani S, Mastouri M, Mhalla S, Karray H, Gargouri S, Bahri O, Trabelsi A, Kallala O, Hannachi N, Chaabouni Y, Smaoui H, Meftah K, Bouhalila SB, Foughali S, Zribi M, Lamari A, Touzi H, Safer M, Alaya NB, Kahla AB, Gdoura M, and Triki H
- Subjects
- Adult, Animals, Humans, Middle Aged, Pangolins, Phylogeny, RNA, Viral, Tunisia epidemiology, COVID-19 epidemiology, COVID-19 virology, Genetic Variation, SARS-CoV-2 genetics
- Abstract
Introduction: The Delta variant posed an increased risk to global public health and rapidly replaced the pre-existent variants worldwide. In this study, the genetic diversity and the spatio-temporal dynamics of 662 SARS-CoV2 genomes obtained during the Delta wave across Tunisia were investigated., Methods: Viral whole genome and partial S-segment sequencing was performed using Illumina and Sanger platforms, respectively and lineage assignemnt was assessed using Pangolin version 1.2.4 and scorpio version 3.4.X. Phylogenetic and phylogeographic analyses were achieved using IQ-Tree and Beast programs., Results: The age distribution of the infected cases showed a large peak between 25 to 50 years. Twelve Delta sub-lineages were detected nation-wide with AY.122 being the predominant variant representing 94.6% of sequences. AY.122 sequences were highly related and shared the amino-acid change ORF1a:A498V, the synonymous mutations 2746T>C, 3037C>T, 8986C>T, 11332A>G in ORF1a and 23683C>T in the S gene with respect to the Wuhan reference genome (NC_045512.2). Spatio-temporal analysis indicates that the larger cities of Nabeul, Tunis and Kairouan constituted epicenters for the AY.122 sub-lineage and subsequent dispersion to the rest of the country., Discussion: This study adds more knowledge about the Delta variant and sub-variants distribution worldwide by documenting genomic and epidemiological data from Tunisia, a North African region. Such results may be helpful to the understanding of future COVID-19 waves and variants., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Haddad-Boubaker, Arbi, Souiai, Chouikha, Fares, Edington, Sims, Camma, Lorusso, Diagne, Diallo, Boubaker, Ferjani, Mastouri, Mhalla, Karray, Gargouri, Bahri, Trabelsi, Kallala, Hannachi, Chaabouni, Smaoui, Meftah, Bouhalila, Foughali, Zribi, Lamari, Touzi, Safer, Alaya, Kahla, Gdoura and Triki.)
- Published
- 2023
- Full Text
- View/download PDF
9. The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance.
- Author
-
Tegally H, San JE, Cotten M, Moir M, Tegomoh B, Mboowa G, Martin DP, Baxter C, Lambisia AW, Diallo A, Amoako DG, Diagne MM, Sisay A, Zekri AN, Gueye AS, Sangare AK, Ouedraogo AS, Sow A, Musa AO, Sesay AK, Abias AG, Elzagheid AI, Lagare A, Kemi AS, Abar AE, Johnson AA, Fowotade A, Oluwapelumi AO, Amuri AA, Juru A, Kandeil A, Mostafa A, Rebai A, Sayed A, Kazeem A, Balde A, Christoffels A, Trotter AJ, Campbell A, Keita AK, Kone A, Bouzid A, Souissi A, Agweyu A, Naguib A, Gutierrez AV, Nkeshimana A, Page AJ, Yadouleton A, Vinze A, Happi AN, Chouikha A, Iranzadeh A, Maharaj A, Batchi-Bouyou AL, Ismail A, Sylverken AA, Goba A, Femi A, Sijuwola AE, Marycelin B, Salako BL, Oderinde BS, Bolajoko B, Diarra B, Herring BL, Tsofa B, Lekana-Douki B, Mvula B, Njanpop-Lafourcade BM, Marondera BT, Khaireh BA, Kouriba B, Adu B, Pool B, McInnis B, Brook C, Williamson C, Nduwimana C, Anscombe C, Pratt CB, Scheepers C, Akoua-Koffi CG, Agoti CN, Mapanguy CM, Loucoubar C, Onwuamah CK, Ihekweazu C, Malaka CN, Peyrefitte C, Grace C, Omoruyi CE, Rafaï CD, Morang'a CM, Erameh C, Lule DB, Bridges DJ, Mukadi-Bamuleka D, Park D, Rasmussen DA, Baker D, Nokes DJ, Ssemwanga D, Tshiabuila D, Amuzu DSY, Goedhals D, Grant DS, Omuoyo DO, Maruapula D, Wanjohi DW, Foster-Nyarko E, Lusamaki EK, Simulundu E, Ong'era EM, Ngabana EN, Abworo EO, Otieno E, Shumba E, Barasa E, Ahmed EB, Ahmed EA, Lokilo E, Mukantwari E, Philomena E, Belarbi E, Simon-Loriere E, Anoh EA, Manuel E, Leendertz F, Taweh FM, Wasfi F, Abdelmoula F, Takawira FT, Derrar F, Ajogbasile FV, Treurnicht F, Onikepe F, Ntoumi F, Muyembe FM, Ragomzingba FEZ, Dratibi FA, Iyanu FA, Mbunsu GK, Thilliez G, Kay GL, Akpede GO, van Zyl GU, Awandare GA, Kpeli GS, Schubert G, Maphalala GP, Ranaivoson HC, Omunakwe HE, Onywera H, Abe H, Karray H, Nansumba H, Triki H, Kadjo HAA, Elgahzaly H, Gumbo H, Mathieu H, Kavunga-Membo H, Smeti I, Olawoye IB, Adetifa IMO, Odia I, Ben Boubaker IB, Muhammad IA, Ssewanyana I, Wurie I, Konstantinus IS, Halatoko JWA, Ayei J, Sonoo J, Makangara JC, Tamfum JM, Heraud JM, Shaffer JG, Giandhari J, Musyoki J, Nkurunziza J, Uwanibe JN, Bhiman JN, Yasuda J, Morais J, Kiconco J, Sandi JD, Huddleston J, Odoom JK, Morobe JM, Gyapong JO, Kayiwa JT, Okolie JC, Xavier JS, Gyamfi J, Wamala JF, Bonney JHK, Nyandwi J, Everatt J, Nakaseegu J, Ngoi JM, Namulondo J, Oguzie JU, Andeko JC, Lutwama JJ, Mogga JJH, O'Grady J, Siddle KJ, Victoir K, Adeyemi KT, Tumedi KA, Carvalho KS, Mohammed KS, Dellagi K, Musonda KG, Duedu KO, Fki-Berrajah L, Singh L, Kepler LM, Biscornet L, de Oliveira Martins L, Chabuka L, Olubayo L, Ojok LD, Deng LL, Ochola-Oyier LI, Tyers L, Mine M, Ramuth M, Mastouri M, ElHefnawi M, Mbanne M, Matsheka MI, Kebabonye M, Diop M, Momoh M, Lima Mendonça MDL, Venter M, Paye MF, Faye M, Nyaga MM, Mareka M, Damaris MM, Mburu MW, Mpina MG, Owusu M, Wiley MR, Tatfeng MY, Ayekaba MO, Abouelhoda M, Beloufa MA, Seadawy MG, Khalifa MK, Matobo MM, Kane M, Salou M, Mbulawa MB, Mwenda M, Allam M, Phan MVT, Abid N, Rujeni N, Abuzaid N, Ismael N, Elguindy N, Top NM, Dia N, Mabunda N, Hsiao NY, Silochi NB, Francisco NM, Saasa N, Bbosa N, Murunga N, Gumede N, Wolter N, Sitharam N, Ndodo N, Ajayi NA, Tordo N, Mbhele N, Razanajatovo NH, Iguosadolo N, Mba N, Kingsley OC, Sylvanus O, Femi O, Adewumi OM, Testimony O, Ogunsanya OA, Fakayode O, Ogah OE, Oludayo OE, Faye O, Smith-Lawrence P, Ondoa P, Combe P, Nabisubi P, Semanda P, Oluniyi PE, Arnaldo P, Quashie PK, Okokhere PO, Bejon P, Dussart P, Bester PA, Mbala PK, Kaleebu P, Abechi P, El-Shesheny R, Joseph R, Aziz RK, Essomba RG, Ayivor-Djanie R, Njouom R, Phillips RO, Gorman R, Kingsley RA, Neto Rodrigues RMDESA, Audu RA, Carr RAA, Gargouri S, Masmoudi S, Bootsma S, Sankhe S, Mohamed SI, Femi S, Mhalla S, Hosch S, Kassim SK, Metha S, Trabelsi S, Agwa SH, Mwangi SW, Doumbia S, Makiala-Mandanda S, Aryeetey S, Ahmed SS, Ahmed SM, Elhamoumi S, Moyo S, Lutucuta S, Gaseitsiwe S, Jalloh S, Andriamandimby SF, Oguntope S, Grayo S, Lekana-Douki S, Prosolek S, Ouangraoua S, van Wyk S, Schaffner SF, Kanyerezi S, Ahuka-Mundeke S, Rudder S, Pillay S, Nabadda S, Behillil S, Budiaki SL, van der Werf S, Mashe T, Mohale T, Le-Viet T, Velavan TP, Schindler T, Maponga TG, Bedford T, Anyaneji UJ, Chinedu U, Ramphal U, George UE, Enouf V, Nene V, Gorova V, Roshdy WH, Karim WA, Ampofo WK, Preiser W, Choga WT, Ahmed YA, Ramphal Y, Bediako Y, Naidoo Y, Butera Y, de Laurent ZR, Ouma AEO, von Gottberg A, Githinji G, Moeti M, Tomori O, Sabeti PC, Sall AA, Oyola SO, Tebeje YK, Tessema SK, de Oliveira T, Happi C, Lessells R, Nkengasong J, and Wilkinson E
- Subjects
- Africa epidemiology, Genomics, Humans, COVID-19 epidemiology, COVID-19 virology, Epidemiological Monitoring, Pandemics, SARS-CoV-2 genetics
- Abstract
Investment in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing in Africa over the past year has led to a major increase in the number of sequences that have been generated and used to track the pandemic on the continent, a number that now exceeds 100,000 genomes. Our results show an increase in the number of African countries that are able to sequence domestically and highlight that local sequencing enables faster turnaround times and more-regular routine surveillance. Despite limitations of low testing proportions, findings from this genomic surveillance study underscore the heterogeneous nature of the pandemic and illuminate the distinct dispersal dynamics of variants of concern-particularly Alpha, Beta, Delta, and Omicron-on the continent. Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve while the continent faces many emerging and reemerging infectious disease threats. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century.
- Published
- 2022
- Full Text
- View/download PDF
10. The value of West Nile virus RNA detection by real-time RT-PCR in urine samples from patients with neuroinvasive forms.
- Author
-
Gdoura M, Fares W, Bougatef S, Inoubli A, Touzi H, Hogga N, Ben Dhifallah I, Hannachi N, Argoubi A, Kacem S, Karray H, Ben Alaya N, and Triki H
- Subjects
- Humans, RNA, Viral genetics, Reproducibility of Results, Reverse Transcriptase Polymerase Chain Reaction, West Nile Fever diagnosis, West Nile Fever epidemiology, West Nile virus genetics
- Abstract
Introduction: Routine laboratory screening is based on the detection of WNV specific IgM and IgG in blood and cerebrospinal fluid. Confirmation is then classically applied by real time RT-PCR (rRT-PCR) in Cerebrospinal fluid (CSF), which often gives negative results due to too short virorachia and late sampling. rRT-PCR was applied-for the first time for routine diagnosis purpose-on urine samples., Methods: During 2018 outbreak in Tunisia, 107 patients presented WNV neurologic symptoms and were positive for WNV serology. Of them, 95 patients were sampled for urine and 35 were sampled for CSF. Qualitative rRT-PCR was performed on both type of samples., Results: WNV RNA was detected in 50.5% of urine samples (48/95) and in 2.8% of CSF samples (1/35). WNV RNA was detectable from day 1 to day 41 from symptom onset, however, positive urine rate was 53.1% during the first 10 days from symptom onset. The proportions of urine-positive and urine-negative samples, based on day of collection, showed no statistical difference (p > 0.005). Cycle threshold (Ct) values ranged from 12 to 39, with no correlation with the day of collection. The lowest Ct value was detected for urine sampled on day 5 after symptom onset. A statistically significant difference was found between age groups of confirmed and non confirmed cases (p < 0.001)., Discussion/conclusion: Our study reported the use of rRT-PCR on urine samples as a confirmatory diagnostic tool for WNV "probable cases" during an outbreak. Our findings underlined the reliability and the rapidity of this confirmatory tool, even late, and showed its superiority on CSF investigation., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
11. Clinical characteristics and outcomes of critically ill COVID-19 patients in Sfax, Tunisia.
- Author
-
Bahloul M, Kharrat S, Chtara K, Hafdhi M, Turki O, Baccouche N, Ammar R, Kallel N, Hsairi M, Chakroun-Walha O, Hamida CB, Chelly H, Mahfoudh KB, Karoui A, Karray H, Rekik N, and Bouaziz M
- Abstract
Background: Africa, like the rest of the world, has been impacted by the coronavirus disease 2019 (COVID-19) pandemic. However, only a few studies covering this subject in Africa have been published., Methods: We conducted a retrospective study of critically ill adult COVID-19 patients-all of whom had a confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection- admitted to the intensive care unit (ICU) of Habib Bourguiba University Hospital (Sfax, Tunisia)., Results: A total of 96 patients were admitted into our ICU for respiratory distress due to COVID-19 infection. Mean age was 62.4±12.8 years and median age was 64 years. Mean arterial oxygen tension (PaO2)/fractional inspired oxygen (FiO2) ratio was 105±60 and ≤300 in all cases but one. Oxygen support was required for all patients (100%) and invasive mechanical ventilation for 38 (40%). Prone positioning was applied in 67 patients (70%). Within the study period, 47 of the 96 patients died (49%). Multivariate analysis showed that the factors associated with poor outcome were the development of acute renal failure (odds ratio [OR], 6.7; 95% confidence interval [CI], 1.75-25.9), the use of mechanical ventilation (OR, 5.8; 95% CI, 1.54-22.0), and serum cholinesterase (SChE) activity lower than 5,000 UI/L (OR, 5.0; 95% CI, 1.34-19)., Conclusions: In this retrospective cohort study of critically ill patients admitted to the ICU in Sfax, Tunisia, for acute respiratory failure following COVID-19 infection, the mortality rate was high. The development of acute renal failure, the use of mechanical ventilation, and SChE activity lower than 5,000 UI/L were associated with a poor outcome.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.